Moderna has just entered the biotech market in Spain. The American biotech company, one of the main companies in the development and research of the COVID-19 vaccine, enters the Spanish market with the creation of a subsidiary. Moderna is one of the companies that will surely supply vaccines to Europe. According to the information available through the Commercial Registry, Moderna’s Spanish subsidiary is called Moderna Biotech Spain. This company has just been legally incorporated, although it was previously known as Directorship Cibeles.
Since last week, Moderna’s Spanish subsidiary operates under the name Moderna Biotech Spain and has changed its corporate purpose to: “development, import, manufacture, marketing and distribution of drugs, vaccines and medicines based on messenger RNA”. The sole administrator of this company is Lori Henderson, general counsel of Moderna.
Find out more details about the plans Moderna has regarding the manufacturing and marketing of its COVID-19 vaccine and read the latest finance news with the Born2Invest mobile app.
Moderna plans to build an mRNA technology platform and infrastructure to accelerate drug discovery
Since its founding in 2010, Moderna has been working to build an mRNA technology platform and infrastructure to accelerate drug discovery. Its portfolio includes development candidates for vaccines and mRNA-based therapies that span several therapeutic areas and has several ongoing clinical trials with other development candidates moving towards the clinical side.
The company is working on the development of its coronavirus vaccine from Norwood, Massachusetts (USA). This Cambridge-based laboratory has made headlines for its agreement with Lonza Group. Both companies agreed in early May to manufacture one billion doses per year. The company has been led by Stéphane Bancel, its CEO since July 2011. The executive has a Master’s degree in Engineering from Ecole Centrale Paris and an MBA from Harvard Business School. He was a country manager at Eli Lilly in Belgium and CEO of BioMerieux, a company specialized in in vitro diagnostics.
In addition to Moderna, Bancel is on the board of directors of Qiagen, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, as well as Syros Pharmaceuticals.
The company aims to supply one billion doses of its vaccine from 2021
Last August, the European Commission (EC) acknowledged discussions with Moderna for the contract to purchase eighty million doses of its coronavirus vaccine.
However, the amount of the agreement was not disclosed at the time. According to the president of the EC, Ursula von der Leyen, Brussels will buy eighty million doses for the countries of the European Union from the American pharmaceutical company and will have the option of buying another eighty million.
The transaction will take place once it has been demonstrated that the vaccine is safe and effective in combating COVID-19. Moderna’s phase 3 study began on July 27th with 30,000 participants. The pharmaceutical company has increased its worldwide manufacturing with the goal of providing 500 million doses of the coronavirus per year with the possibility of reaching one billion from 2021. According to the results for the first quarter of 2020, U.S. biotechnology reached revenues of $8 billion (€7.4 billion).
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Genomcore Finalizes its Entry into the United Kingdom after Increasing its Turnover by 73% in 2021
Genomcore has recently entered the market in the United Kingdom. In 2020, the company had a turnover of $912,000 (€750,000),...
The Fintech Ecosystem in Colombia Exceeds 322 Companies
The digital credit segment is the leader in Fintech service offerings, followed by payments and corporate finance, according to Fintank...
Valsabbina Bank and Siav Purchase 25% of MyCreditService
Valsabbina Bank and Siav will purchase 25% of MyCreditService, as part of an investment agreement. The entry of the two...
Cybersecurity Rising Among America’s Infrastructure Priorities
The proposed budget allocates $110 million to the Cybersecurity and Infrastructure Security Agency. Another $750 million is targeted for additional...
Axes Enters the Fertility Business in Spain: the Group Buys Ovoclinic Barcelona
Axes Capital is an international family office focused on investments in the following sectors: healthcare, real estate and renewable energies....
Cannabis7 days ago
On the Way to Cannabis Legalization: Frankfurt Positions Itself as a Pioneer
Featured7 days ago
Ant Group Creates a New Fintech Company: Chongqing Ant
Featured6 days ago
Crowdfunding for the Creation of a Legal Defense Fund for Wind Power Projects Completed
Business7 days ago
Fed’s Tools are Broken